Resurrection of response-guided therapy for sofosbuvir combination therapies

J Hepatol. 2016 Sep;65(3):462-4. doi: 10.1016/j.jhep.2016.05.028. Epub 2016 May 27.

Authors

Harel Dahari¹, Phillippe Halfon², Scott J Cotler³

Affiliations

¹ The Program for Experimental and Theoretical Modeling, Division of Hepatology, Loyola University Medical Center, Maywood, IL, USA. Electronic address: hdahari@lumc.edu.
² Internal Medecine and Infectious Disease Hopital Europeen, Laboratoire Alphabio, Marseille, France.
³ The Program for Experimental and Theoretical Modeling, Division of Hepatology, Loyola University Medical Center, Maywood, IL, USA.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antiviral Agents
Drug Therapy, Combination
Genotype
Hepacivirus
Hepatitis C, Chronic*
Humans
Ribavirin
Sofosbuvir*

Substances

Antiviral Agents
Ribavirin
Sofosbuvir

Grants and funding

R01 AI078881/AI/NIAID NIH HHS/United States